tinengotinib

Tinengotinib is an orally available small molecule multi–kinase inhibitor with antineoplastic and immunomodulatory activity. It selectively inhibits Aurora kinases A and B (AKs), Janus kinases (JAKs), fibroblast growth factor receptors (FGFRs 1–3), and vascular endothelial growth factor receptors (VEGFRs). By targeting these kinases—key drivers of cell proliferation, angiogenesis, and immune response modulation—tinengotinib disrupts tumor cell division and neovascularization in a variety of cancer types. It has demonstrated promising efficacy in advanced or metastatic solid tumors including cholangiocarcinoma with FGFR alterations refractory to prior FGFR inhibitors. Tinengotinib is under investigation in phase II/III clinical trials for cholangiocarcinoma and other solid tumors.[1][5][6][7][8][9][10]

Other names

TINENGOTINIB [INN]UNII-WZ9TJ0L9Y8UNII-WZ-9TJ0L9Y8UNII-WZ 9TJ0L9Y84-(5-(2-Chlorophenyl)-3-Methyl-2,10-Dihydropyrazolo[4,3-B] Pyrido[4,3-E][1,4]Diazepin-8-Yl) Morpholine5-(2-chlorophenyl)-3-methyl-8-(morpholin-4-yl)-1,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepine